ESTROGENIC SUBSTANCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTROGENIC SUBSTANCE (ESTROGENIC SUBSTANCE).
Estrogens bind to and activate nuclear estrogen receptors (ERα and ERβ), leading to gene transcription and regulation of reproductive tissues and secondary sexual characteristics.
| Metabolism | Estrogenic substances are metabolized primarily in the liver via hydroxylation (CYP3A4) and conjugation (glucuronidation and sulfation). Major metabolites include estrone, estradiol, and estriol, which undergo enterohepatic recirculation. |
| Excretion | Primarily renal as glucuronide and sulfate conjugates; approximately 60-80% excreted in urine, 10-30% in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 13-27 hours for endogenous estrogens, with clinically therapeutically relevant metabolites having half-lives up to 24-36 hours, allowing once-daily dosing. |
| Protein binding | Approximately 97-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Approximately 10-15 L/kg, indicating extensive tissue distribution, binding to estrogen receptors, and accumulation in fat stores. |
| Bioavailability | Oral: 5-10% due to extensive first-pass metabolism; intramuscular: 100% (given as esterified prodrug); transdermal: approximately 100% relative to IV, avoiding first-pass metabolism. |
| Onset of Action | Oral: 2-4 hours for clinical effects (e.g., estrogenic effects on vaginal epithelium); intramuscular: 1-2 days; transdermal: steady-state achieved within 2-6 hours after application. |
| Duration of Action | Oral: 24-48 hours; intramuscular: 3-7 days; transdermal: patch duration typically 7 days, with effects sustained as long as patch is worn. |
| Molecular Weight | 272.38 |
0.3 to 1.25 mg orally once daily; 25 to 100 mcg transdermal patch applied twice weekly; 0.5 to 2 mg vaginal cream daily for 3 weeks then 1 week off.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh C); reduce dose by 50% in moderate impairment (Child-Pugh B). |
| Pediatric use | Not typically indicated for pediatric use; in rare cases for induction of puberty, starting dose 0.3 mg orally daily, titrated gradually. |
| Geriatric use | Initiate at lowest effective dose (0.3 mg orally daily or 25 mcg transdermal) to minimize thromboembolic and cardiovascular risks. |
| 1st trimester | Contraindicated in first trimester due to risk of fetal harm, including congenital anomalies (e.g., VACTERL association) and potential carcinogenic effects (clear cell adenocarcinoma in daughters). |
| 2nd trimester | Contraindicated in second trimester; may cause urogenital tract abnormalities and increase risk of preterm birth. |
| 3rd trimester | Contraindicated in third trimester; associated with fetal adrenal suppression, electrolyte disturbances, and potential long-term effects on reproductive development. |
Clinical note
Comprehensive clinical and safety monograph for ESTROGENIC SUBSTANCE (ESTROGENIC SUBSTANCE).
| Placental transfer | Significant; estrogens readily cross the placenta and can achieve fetal concentrations comparable to maternal levels. |
| Breastfeeding | Estrogens are excreted in breast milk in small amounts and may reduce milk production and quality. Potential for adverse effects in nursing infants, including gynecomastia and vaginal bleeding. Use only if clearly needed and with caution. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) substudies reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years) receiving conjugated estrogens (0.625 mg/day) with medroxyprogesterone acetate. The risk of dementia was also increased. Due to these risks, estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals.
| Serious Effects |
Known or suspected pregnancyBreast cancer (known or suspected)Estrogen-dependent neoplasia (e.g., endometrial cancer)Active thromboembolic disorders or history of thrombosisUndiagnosed abnormal genital bleedingKnown hypersensitivity to estrogen
| Precautions | Cardiovascular disorders (increased risk of MI, stroke, VTE), malignant neoplasms (endometrial and breast cancer), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, elevated blood pressure, hypertriglyceridemia, and impaired liver function. Should be discontinued if jaundice occurs. Not for use during pregnancy. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Exposure associated with increased risk of congenital anomalies including cardiovascular defects and limb reduction defects. Second/third trimester: Potential for urogenital tract abnormalities in female offspring. Use contraindicated in pregnancy. |
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, and hepatic dysfunction in mother. Fetal ultrasound for structural anomalies if inadvertent exposure occurs. |
| Fertility Effects | May inhibit ovulation and impair fertility during use. Effects are reversible upon discontinuation. Long-term use may affect menstrual cycle regularity. |
| Grapefruit and grapefruit juice may increase estrogen levels and risk of side effects; avoid concurrent consumption. No other significant food interactions known. |
| Clinical Pearls | Conjugated estrogens are typically dosed cyclically with a progestin in women with an intact uterus to prevent endometrial hyperplasia. Estrogen therapy increases risk of venous thromboembolism and stroke; avoid in patients with history of these events. Transdermal administration avoids first-pass metabolism and may lower thromboembolic risk. Use lowest effective dose for shortest duration. Not recommended for prevention of cardiovascular disease or dementia. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily at the same time. · If you have a uterus, you may need to take a progestin with estrogen to reduce the risk of endometrial cancer. · Report any signs of blood clots (sudden chest pain, shortness of breath, leg pain/swelling), stroke (numbness/weakness, vision/speech changes), or breast lumps promptly. · Avoid smoking while taking estrogens, as it increases the risk of serious cardiovascular side effects. · This medication does not protect against HIV or other sexually transmitted infections. |